Ascendis Pharma Says Trial Results Show 'Meaningful Improvements' in Kidney Function in Adults with Hypoparathyroidism

09:31 AM EDT, 10/26/2026 (MT Newswires) -- Ascendis Pharma (ASND) said Monday new results showed "early, sustained, and clinically meaningful improvements" in renal function in adults with hypoparathyroidism given TransCon PTH for up to five years in phase 2 and phase 3 trials. Increases in mean estimated glomerular filtration rate compared with baseline were "statistically significant" in people given the treatment from week 26 until trial completion, the company said. The trials comprised 141 adults with hypoparathyroidism and the pooled kidney data analysis covered 139 patients who were given at least one dose of TransCon PTH, Ascendis said.